Objective: To evaluate the clinical significance of lymphovascular invasion (LVI) on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection Methods: This retrospective study was performed with 155 patients with newly diagnosed pT1 urothelial carcinoma of bladder who were treated with transurethral resection of bladder tumor (TURBT) at our institution from January 2006 to January 2010. The presence or absence of LVI was examined according to our pathologists. Chi-square was performed to identify the correlations between LVI and other clinical and pathological features. Kaplan-Meier method was used to estimate the recurrence-free survival (RFS) and progression-free survival (PFS) curves and difference was determined by the log-rank test. Univariate and multivariate analyses were performed to determine the predictive factors through a Cox proportional hazards regression model. Results: LVI was detected in a total of 34 patients (21.9%). While LVI was associated with high grade tumors (P<0.001) and intravesical therapy (P=0.009). Correlations with age (P=0.227), gender (P=0.376), tumor size (P=0.969), tumor multiplicity (P=0.196), carcinoma in situ (CIS) (P=0.321) and smoking (P=0.438) were not statistically significant. There was a statistically significant tendency towards higher recurrence rate and shorter RFS time in LVI-positive patients. However, no statistically significant differences were observed in progression rate between the two groups. Moreover, multivariate Cox proportional hazards analysis revealed that LVI, tumor size and smoking were independent prognostic predictors of recurrence. The hazard ratios (95% confidence interval) were 2.042 (1.113-3.746, P=0.021), 1.817 (1.014-3.256, P=0.045) and 2.079 (1.172-3.687, P=0.012) respectively. Conclusions: The presence of LVI in TURBT specimens is significantly associated with higher recurrence rate and shorter RFS time in patients with newly diagnosed T1 urothelial carcinoma of the bladder. It is an independent prognostic predictor for disease recurrence. Thus, patients with LVI should be followed up closely.
Objective: To study the histology and pathology clinical features, diagnosis, identification and treatment of mixed epithelial and stromal tumor of the kidney (MESTK). Methods: One case of MESTK was reported. One patient's clinical data with mixed epithelial and stromal tumor of the kidney in our department was reported. Male, 53 years old, physical examination found the left kidney cyst. B-ultrasonic, ultrasonic imaging and CT of the left kidney and upper lateral visible cysts, size 7.5×6.4×6.4 cm, and the adjacent in the renal sinus cyst space form, can be seen in the space limitations, involving the scope of 6.5×2.8×2.8 cm. Retrieve PubMed and domestic literature of CNKI database, reported a total of 160 cases, including malignant change in 12 cases of foreign literature, and their clinical data were reviewed. Results: Patient with surgical treatment had complete resection of the tumor and ipsilateral kidney. The tumor consisted of multiple cystic and solid areas on gross examination, and intracapsular surface coating flat, cubic, hobnail and stratified epithelium, partial epithelial hyperplasia, have formed at the regional and ventricular papillary structures. Local tissue is at early invasive. Immunohistochemistry: Vimentin (+), CK7 (+), Pax8 (−), SAM partial (+), P504s weak (+), TFE3 partial (+), ER (−), PR (+), Ki67 <1% positive tumor cells. There was no evidence of recurrence and metastasis during the follow-up of 6 months. Conclusions: MESTK on domestic and foreign clinical is rare, and has non-specific clinical manifestations. Additionally, surgery is the main therapy for MESTK and there is the possibility of malignant and malignant lesions has no effective treatment. Objective: To evaluate the value of extensive transurethral resection (TUR) in the diagnosis and treatment of nonmuscle invasive bladder cancer (NMIBC) and its further impact on the recurrence rate at the first follow-up cystoscopy (RR-FFC). Methods: A retrospective review of consecutive series of 523 patients with NMIBCs who underwent TUR from June 2009 to July 2015 at our institution. Extensive TURs were performed by taking additional tumor base and marginal specimens for 317 patients (group 1). Extensive TURs were not done in the other 206 patients (group 2). Urine cytology and follow-up cystoscopy were performed at 3-mo after the initial TUR. To observe the positive findings of additional specimens and whether the diagnosis and treatment plan changed in group 1. There was also a comparison of the RR-FFC between group1 and group 2. Results: There were 51/317 (16.1%) patients whose additional specimens revealed pathological findings such as Ta, T1, and carcinoma in situ (Tis) diseases. Of these positive findings, 6/51 (11.8%) were Ta 
